DOI QR코드

DOI QR Code

Treatment Outcomes of Brain metastasis from Papillary Thyroid Cancer

갑상선 유두암 뇌전이의 치료 효과

  • Bae, Hyeonwoo (Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Kim, Seok-Mo (Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Kim, Soo Young (Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Chang, Ho Jin (Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Kim, Bup-Woo (Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Lee, Yong Sang (Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Chang, Hang-Seok (Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Park, Cheong Soo (Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine)
  • 배현우 (연세대학교 강남세브란스병원 갑상선암센터) ;
  • 김석모 (연세대학교 강남세브란스병원 갑상선암센터) ;
  • 김수영 (연세대학교 강남세브란스병원 갑상선암센터) ;
  • 장호진 (연세대학교 강남세브란스병원 갑상선암센터) ;
  • 김법우 (연세대학교 강남세브란스병원 갑상선암센터) ;
  • 이용상 (연세대학교 강남세브란스병원 갑상선암센터) ;
  • 장항석 (연세대학교 강남세브란스병원 갑상선암센터) ;
  • 박정수 (연세대학교 강남세브란스병원 갑상선암센터)
  • Received : 2017.10.17
  • Accepted : 2018.03.27
  • Published : 2018.05.30

Abstract

Background/Objectives: Brain metastasis (BM) is a rare form of distant metastasis with papillary thyroid cancer (PTC). Patients with BM of PTC carry a poor prognosis. The aim of this study was to contribute to the understanding of this disease by analyzing patients with BM of PTC. Materials & Methods: Between March 2003 and December 2013, the patient database was conducted to identify thyroid cancer patients treated. Among the 22,758 thyroid cancer patients, 14 (0.06 %) were identified to have metastasis to the brain during follow-up. The medical records of 14 patients with BM were retrospectively reviewed, focusing on the following: patient characteristics, synchronous or previous distant metastasis, treatments including whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS) and surgery, and characteristics on radiologic findings, time interval between first diagnosis of primary thyroid cancer and BM and survival after BM. Results: The mean age at initial diagnosis and BM were $50.9{\pm}15.8years$ and $61.3{\pm}12.7years$. The mean duration between initial diagnosis and BM was $10.4{\pm}7.9years$. Patients were treated with varied combinations of surgery, SRS and WBRT except 4 patients who had refused treatment. The median overall survival (OS) time after BM diagnosis was 10 months (range 1 - 19). Patients receiving treatment (WBRT and/or surgery, SRS) had a significant longer median OS of 16.5 months in comparison to 3.5 months for those treated without treatment. (p = 0.005) Conclusion: Patients who received aggressive treatment had a longer OS than those with only supportive care. Treatment such as surgery, SRS and WBRT should be considered in patients with BM.

Keywords

References

  1. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma:100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab. 1995;80:2041-2045.
  2. Lin JD, Huang MJ, Juang JH, Chao TC, Huang BY, Chen KW, et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid. 1999;9:1227-1235. https://doi.org/10.1089/thy.1999.9.1227
  3. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899. https://doi.org/10.1210/jc.2005-2838
  4. Henriques de Figueiredo B, Godbert Y, Soubeyran I, Carrat X, Lagarde P, Cazeau AL, et al. Brain metastases from thyroid carcinoma:a retrospective study of 21 patients. Thyroid. 2014;24:270-276. https://doi.org/10.1089/thy.2013.0061
  5. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab. 1997;82:3637-3642. https://doi.org/10.1210/jcem.82.11.4386
  6. Hoie J, Stenwig AE, Kullmann G, Lindegaard M. Distant metastases in papillary thyroid cancer. A review of 91 patients. Cancer. 1988;61:1-6. https://doi.org/10.1002/1097-0142(19880101)61:1<1::AID-CNCR2820610102>3.0.CO;2-R
  7. Choong NW, Gore E. Stereotactic radiosurgery for the management of brain metastases. N Engl J Med. 2010;363:592; author reply 592-593.
  8. Bernad DM, Sperduto PW, Souhami L, Jensen AW, Roberge D. Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers. J Neurooncol. 2010;98:249-252. https://doi.org/10.1007/s11060-010-0175-z
  9. Tahmasebi FC, Farmer P, Powell SZ, Aldape KD, Fuller GN, Patel S, et al. Brain metastases from papillary thyroid carcinomas. Virchows Arch. 2013;462:473-480. https://doi.org/10.1007/s00428-013-1394-4
  10. McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, Buckner JC. Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer. 2003;98:356-362. https://doi.org/10.1002/cncr.11488
  11. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501-511. https://doi.org/10.1016/S0140-6736(03)12488-9
  12. Biswal BM, Bal CS, Sandhu MS, Padhy AK, Rath GK. Management of intracranial metastases of differentiated carcinoma of thyroid. J Neurooncol. 1994;22:77-81. https://doi.org/10.1007/BF01058357
  13. Miranda ER, Padrao EL, Silva BC, De Marco L, Sarquis MS. Papillary thyroid carcinoma with brain metastases: an unusual 10-year-survival case. Thyroid. 2010;20:657-661. https://doi.org/10.1089/thy.2009.0442
  14. Aguiar PH, Agner C, Tavares FR, Yamaguchi N. Unusual brain metastases from papillary thyroid carcinoma: case report. Neurosurgery. 2001;49:1008-1013.
  15. Ye X, Zhu Y, Cai J. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature. J Cancer Res Ther. 2015;11 Suppl 2:C185-190. https://doi.org/10.4103/0973-1482.168182
  16. Boudou-Rouquette P, Thomas-Schoemann A, Bellesoeur A, Goldwasser F. Sorafenib for patients with differentiated thyroid cancer. Lancet. 2015;385:227-228. https://doi.org/10.1016/S0140-6736(15)60054-X